Two programs presented at ESMO 2024: » Status update for the ongoing Phase 1/2a study with the company's second anti-TNFR2 antibody BI-1910. » Results from the ongoing Phase 1/2a trial with the ...

including our TNFR2 antibody and bispecific programs," said Howard W. Robin, President and CEO of Nektar Therapeutics. "We believe Ampersand is an optimal partner to lead the manufacturing ...

SOUTH SAN FRANCISCO, CA, USA I 13, 2024 I TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create ...